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Abstract
Background: To support policy making, we developed an initial model to assess the cost-effectiveness of potential
strategies to increase influenza vaccination rates among children in China.
Methods: We studied on children aged 6 months to 14 years in four provinces (Shandong, Henan, Hunan, and Sichuan),
with a health care system perspective. We used data from 2005/6 to 2010/11, excluding 2009/10. Costs are reported in 2010
U.S. dollars.
Results: In comparison with no vaccination, the mean (range) of Medically Attended Cases averted by the current self-
payment policy for the two age groups (6 to 59 months and 60 months to 14 years) was 1,465 (23,11,132) and 792
(36,4,247), and the cost effectiveness ratios were $ 0 (-11-51) and $ 37 (6-125) per case adverted, respectively. In
comparison with the current policy, the incremental cost effectiveness ratio (ICER) of alternative strategies, OPTION One-
reminder and OPTION Two-comprehensive package, decreased as vaccination rate increased. The ICER for children aged 6
to 59 months was lower than that for children aged 60 months to 14 years.
Conclusions: The model is a useful tool in identifying elements for evaluating vaccination strategies. However, more data
are needed to produce more accurate cost-effectiveness estimates of potential vaccination policies.
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Introduction
Influenza can increase acute respiratory infections and hospital
admissions, imposing a significant burden of illness among
vulnerable groups including children. The World Health Orga-
nization (WHO) and many countries recommend annual influenza
vaccines for children [1–3]. In 2003, the Chinese Ministry of
Health issued the first guidance on seasonal influenza vaccination
[4]. Prior to the start of each influenza season since 2007, the
Chinese Center for Disease Control and Prevention (China CDC)
released annual seasonal influenza vaccination guidance recom-
mending that children should be included in the priority
population [5–8]. Nonetheless, the influenza vaccination rate
among children in China remains low, in part due to a low level of
available vaccine supply sufficient for 1.9% of the Chinese
population [9].
China’s influenza vaccination program is administered by the
CDC system. Every year, local governments authorize local CDCs
to purchase vaccine before the influenza season and deploy to
vaccination clinics. These clinics are usually located in close
proximity to the local CDC or other community health care
centers, but not in hospitals. Patients have to pay for the
vaccination, except in a few cities such as Beijing. The influenza
vaccination policy has not been modified for many years because
decision makers lack scientific evidence on the impact of
alternative strategies.
The objective of this study is to present for public health policy
makers, an initial model, using both available data and assump-
tions, to evaluate the cost-effectiveness of the current influenza
vaccination policy in children as well as other alternative influenza
vaccination strategies in China.
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Methods
We built a spreadsheet-based model to evaluate the cost-
effectiveness of current seasonal influenza vaccination policies in
children aged 6 months to 14 years in four provinces (Shandong,
Henan, Hunan, and Sichuan) in China. We also developed a
methodology to evaluate the cost-effectiveness of using alternative
strategies to increase the influenza vaccination coverage rate
among children in China. All analyses are from the health care
system perspective with the government as the payer. Our study
focused on patients who attended government-run hospitals and
clinics. Costs are reported in 2010 U.S. dollars. We did not
discount any cost or health outcomes as each influenza season lasts
less than one year.
Variables to estimate the number of cases
The population (P) for the model was census data for calendar
year 2009 [10]. Two age groups of children were analyzed, 6 to 59
months and 60 months to 14 years. See Table S1 in Appendix S1
for specific provincial population numbers.
We used five years of epidemiological data from the season
2005/06 to 2010/11 according to Chinese Influenza-Like-Illness
(ILI) sentinel surveillance system, excluding the 2009/10 season
which was influenza pandemic, causing an extraordinary public
health response with large vaccination coverage [11]. See Table
S2 in Appendix S1 for specific seasonal and provincial numbers.
Number of outpatients and inpatients: We estimated the
number of confirmed influenza outpatients among children using
the following equation:
# confirmed influenza outpatients = rate of outpatient visits
(p1)6rate of ILI cases in outpatients (p2) 6influenza positive rate
among ILI (p3) 6population (P)
Data for the rate of outpatient visits for all causes (p1) (Table 1)
came from the 4th National Health Services Survey [12], which
asked for respondents’ outpatient visits in the previous two weeks.
Assuming the influenza season lasted for 24 weeks, we then
multiplied the rate of outpatient visits in 2 weeks by 12 to get the
overall rate of the influenza season.
The rate of ILI (p2) and influenza positive rate among ILI (p3)
were from the Chinese ILI sentinel surveillance system, which
records demographic, clinic visit and laboratory testing data by
specific province.
We used the following equation to calculate the number of
confirmed influenza inpatients:
# confirmed influenza inpatients = ((rate of outpatient visits (p1)
6 rate of ILI cases in outpatients (p2))/rate of ILI outpatients per
Severe Acute Respiratory Infection (SARI) hospitalization (p4))
6influenza positive rate among SARI cases (p5) 6population (P)
We used Chinese sentinel SARI surveillance data, from Oct 1,
2010 to Mar 31, 2011, to calculate the rate of ILI outpatients per
SARI inpatient (p4) (Table 1). The SARI surveillance hospitals
were also the ILI surveillance hospitals. Patients who met the
SARI definitions [13] were eligible for enrollment and nasopha-
ryngeal and throat swabs were collected for influenza viruses
testing as described previously [13,14]. Once each SARI case is
tested for influenza virus, we then have the influenza positive rate
per 100 SARI cases (p5).
Number of cases adverted: We collected the age and
province specific influenza vaccination coverage rate for seasons
2010/11 and 2011/12 from telephone surveys conducted by
China CDC in 2011 (Table 1 and Table S3 in Appendix S1) [15].
We also used the annual sales of influenza vaccine to estimate the
coverage rate for season 2005/06 to 2008/09, and assumed the
coverage rate was the same for children in both age groups.
The influenza vaccine effectiveness by age group was collected
from published literature [16–20]. The mean was 61% with range
of 52% to 68% (Table 1).
In this study we used the health outcome of Medically Attended
Cases (MAC), excluding those who do not seek medical care in
public health facilities.
We applied the following equation to generate the number of
cases averted:
# cases averted (both outpatient and inpatient) = (# confirmed
influenza outpatients + # confirmed influenza inpatients)/(1 – %
vaccine coverage6% vaccine effectiveness) 6% vaccine cover-
age6% vaccine effectiveness
Variables used to estimate the economic impact of
vaccination
Program and vaccine cost: Data were not available on the
programmatic cost of the influenza vaccination program in China.
However, the Expanded Program of Immunization (EPI) system
shares the same management system with the influenza vaccina-
tion program and those data are documented in previous reports
[21]. The programmatic cost of the EPI system per dose per child
was $ 1.69, including staff payment at provincial, prefecture and
county level, program operation (i.e. advertisement, training, and
monitoring), logistics, and cold-chain (Table 2).
In China, influenza vaccines are purchased from both domestic
and international suppliers. We assumed that vaccine cost was the
same as the purchase price. In season 2010/11, the mean (range)
government purchase price of influenza vaccine for children was $
3.20 (2.89–3.38) for domestic suppliers and $ 6.59 (6.43–6.75) for
international suppliers.
Based on sales from 2010/11, we estimated that 78% of the
vaccines purchased were from domestic suppliers and 22% were
from international suppliers [9]. Therefore our weighted average
of government purchase price was $ 3.95.
Under the current policy, patients pay $ 4.52 (3.94–4.87) for
domestic vaccine and $ 9.49 (8.57–9.65) for vaccines produced by
international companies (authors’ unpublished data), with a
weighted average of $ 5.61 in the four provinces.
We used the following equation to determine the cost of the
influenza vaccination program to the government (per child per
dose) under the current self-payment policy:
Cost of influenza vaccination program to the government (per
child per dose) = Programmatic cost per child per dose + cost of
influenza vaccine per dose to government - price paid by parents
per dose = $1.69 + $3.95 2 $5.61 = $ 0.03.
Cost of illness (Outpatient and inpatient costs): We
used the health care system perspective with the government as the
payer. Our study focused on patients who attended government-
run hospitals and clinics, and we only included the cost borne by
the health care system. We did not include patient co-payments,
direct non-medical cost and lost productivity.
The cost of confirmed influenza outpatient and inpatient cases
for children aged 6 months to 14 years was estimated $ 11.28 and
$ 284.44, respectively. The estimated reimbursement rate from the
survey was 19.25% for children. Parents paid the remainder.
Therefore, the health care system paid $2.17 per outpatient case
and $54.67 per inpatient case. The estimated cost and reimburse-
ment rate was based on a survey [13].
Cost-effectiveness analysis of the current policy
Expected costs, outcomes, and cost effectiveness ratios (CERs)
were calculated in the spreadsheet model for each of the four
provinces and the two age groups from season 2005/06 to 2010/11,
Influenza Vaccination Cost-Effectiveness, China
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excluding season 2009/10. CERs were reported as cost per case
averted for the current influenza vaccination program compared
with no vaccination.
We used historical data on clinical visits and vaccination
coverage rates in the four provinces as the best available data to
model the natural fluctuation of influenza prevalence and
vaccination coverage rate.
Table 1. Epidemiology input data of model.
Parameter and definition Age group Mean or Median (range) Source
P Population 6–59 ms 14,301,091 Statistic yearbook in China, 2009 [10]
60 ms-14 yrs 45,737,342
p1 Number of outpatients of age specific
visit per 100 persons of all age for any
cause in influenza season (6 months)
6–59 ms 297.60 4th national health service research in 2008 [12]
60 ms-14 yrs 109.20
p2 ILI of age specific per 100 outpatients
of all age
6–59 ms 1.58 (0.22, 3.30) ILI sentinel surveillance, CCDC (from 05/06 to 10/11
except 09/10 season)
60 ms-14 yrs 0.55 (0.16, 0.99)
p3 Influenza positive per 100 ILI with lab
test of age specific
6–59 ms 9.08 (6.95, 11.30) ILI sentinel surveillance, CCDC (from 05/06 to 10/11
except 09/10 season)
60 ms-14 yrs 17.47 (14.77, 22.72)
p4 ILI outpatients of age specific per SARI
hospitalization in same SARI sentinel
hospital
6–59 ms 5.63 (0.32–593.63) Data of cost survey in three SARI sentinel hospitals in
2011
60 ms-14 yrs 8.58 (0.75–941.00)
p5 Number of influenza positive per 100
SARI cases
6 ms-14 yrs 14.97 Data of cost survey in three SARI sentinel hospitals in
2011
VCR Influenza vaccination coverage rate (%) 6–59 ms 11.85 (1.18, 37.69) (1)VCR of 05/06-08/09 are assumed as ratio of sales vs
pop, and VCR of two age groups are assumed same;
(2)VCR of 10/11 and 11/12 were from telephone survey
in five provinces conducted by CCDC in 2011
60 ms-14 yrs 10.81 (1.18, 39.09)
VE Influenza vaccine effectiveness (%) 6 ms-14 yrs 61 (52, 68) A.S. Monto et al, 2009 [15], D.M. Skowronski et al, 2007
[16,17] Eelko Hak, et al, 2000 [18], Steens A, et al, 2011
[19]
Footnotes: ms: months; yrs: years. See Table S2 in Appendix S1 for specific seasonal and provincial numbers.
doi:10.1371/journal.pone.0087590.t001
Table 2. Cost input data of model.
Parameter and definition Group Value (US$) Source





Cost of influenza vaccine per dose Government purchase price 3.95 Sichuan’s data, authors’
unpublished data
Vaccination fee Vaccination fee to parents 5.61 Sichuan’s data, authors’
unpublished data
Net cost of influenza vaccination program
to government per child per dose
Current policy 0.03 Model calculation
Cost of confirmed influenza outpatient aged 6ms-14 yrs Direct medical cost 11.28 Zhou L, et al, 2013 [13]
Cost of confirmed influenza inpatient aged 6ms-14 yrs Direct medical cost 284.44
Footnotes:
The original currency was CNY and has been converted to USD using exchange rate in 2010 (100 US = 677 CNY).
We only included the cost that was reimbursed by the health insurance, and did not include the proportion that was paid by parents.
The estimated reimbursement rate from the survey was 19.25% for children. Therefore, the health care system paid $2.17 per outpatient case and $54.67 per inpatient
case.
doi:10.1371/journal.pone.0087590.t002
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The equation below was used to calculate the CERs:
$ Cost per case adverted = Net cost/# cases averted = ($ cost
of influenza vaccination program –$ health care cost saved)/#
cases averted
Evaluation of alternative strategies to increase
vaccination rate
We also used this model to evaluate the cost-effectiveness of
alternative strategies.
Price and demand curve: To explore the impact on demand
due to change in vaccine price to parents, we drew a price and
demand curve (Figure 1). Given that the Beijing public health
authority began to subsidize influenza vaccination for school
children in 2007 and to provide free influenza vaccination to
school children in 2009 [22], we compared vaccination coverage
rates in Beijing before and after subsidy and free vaccination. We
also analyzed vaccine coverage rates in Sichuan pre- and post-
pandemic to illustrate the effects of other factors, since there was
no change in price.
OPTION description and assumptions: Experience from
other countries suggests that measures such as providing vaccina-
tion reminders, sending free vaccination vouchers to parents, and
expanding vaccination sites could increase influenza vaccination
rates [23–25]. We constructed two alternative OPTIONs for
increasing vaccination rates based on these experiences with
adjustment for the Chinese situation.
OPTION One is a telephone reminder to parents of targeted
children for influenza vaccination. For example, staff in the EPI
system can call parents before influenza season, reminding them to
bring their children for influenza vaccination. To capture different
levels of impact by this measure, we assumed this could increase
the vaccination rate by 5%, 10%, and 15%. We also assumed that
the current system could absorb a 5% and 10% increase in
vaccination rate, and the program cost per child was assumed to
be the same as prior. When the vaccination rate increased by 15%,
we assumed that the current system would require additional
resources to meet the demand, so the programmatic cost per child
would be 1.5 times prior cost (Table 3).
OPTION Two is a comprehensive package consisting of
providing vouchers for free vaccination, and expanding vaccina-
tion sites to include hospitals. We assumed that this comprehensive
measure could increase the vaccination rate by 10%, 15%, and
25%, and the programmatic cost with this measure was assumed
to be the same as prior, 1.5 times, and 2.5 times prior cost,
respectively.
To meet the increasing demand of vaccination clinics caused by
the increase in vaccination rate, we assumed that in OPTION
Two, vaccination sites will be expanded in hospitals in the
following order: (1) general hospitals for a 10% increase in
vaccination coverage rate, (2) further expanded to half of
traditional and specialized hospitals for a 15% increase, and (3)
to all hospitals for a 25% increase (Table 3) [12]. We assumed
there will be one nurse working in each vaccination site.
Incremental cost effectiveness ratio: We then used the
spreadsheet-based model to calculate the incremental cost
effectiveness ratio (ICER) for each option, compared with the
current situation of the self-payment policy using the formula
below:
ICER (for different options, age groups, and provinces) = $
incremental net cost/# incremental cases averted = ($ incre-
mental cost of influenza vaccination program – $ incremental cost
of health care saved)/(# cases averted by the option – # cases
averted in current situation)
Sensitivity analyses
Although we examined the impact of a wide range of values for
a number of critical inputs (Tables 1 and 2), the spreadsheet model
allows a user to further explore the impact of changes in input
Figure 1. Impact on demand due to price of vaccine change to the parents. This figure used data of vaccination coverage rate and vaccine
price to the parents in Beijing and Sichuan Province from season 05/06 to 11/12, excluding 09/10 the pandemic season. Beijing initiated an influenza
vaccination subsidy policy for children and the elderly in 2007 and 2008, and has provided free influenza vaccine for children and the elderly since
2009.
doi:10.1371/journal.pone.0087590.g001
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values, either as assumptions or as additional data from the field
becomes available.
Ethics statement
The study was reviewed and approved by the Chinese Center
for Disease Control and Prevention Institute Review Board which
is registered with the Office for Human Research Protections
(active no. in 2012 was IRB 00005183) and has a US Federal Wide
Assurance (FWA 00002896). As a study on in-hand surveillance
and survey data with no personal contact and no collection of
personal data, the Chinese Center for Disease Control and
Prevention Institute Review Board waived the need for written
informed consent from the individuals.
Results
Current situation
The mean (per season) MAC averted for the two age groups (6
to 59 months and 60 months to 14 years) was 1,465 (range:
23,11,132) and 792 (36,4,247), respectively, during the studied
five influenza seasons (Table 4).
The cost of the influenza vaccination program to government
for the two age groups was $ 6,983 and $ 17,918, and the CER
was $ 0 (211,51) and $ 37 (6,125) per case adverted,
respectively (Table 4). For age group 6–59 months, the vaccination
program was cost-saving in Henan and Hunan in all studied
seasons, in Shandong in season 05/06 and 10/11, and in Sichuan
in season 10/11. For age group 60 months to 14 years, it was not
cost saving in any season.
Alternative OPTIONs
Cost of OPTIONs: Results for the two alternative strategies
are shown in Table 5 and specific seasonal and provincial data are
in Table S6 in Appendix S1.
OPTION One would cost an additional $ 0.17 per child per
dose for 5% and 10% increased vaccination rate, and $ 1.02 per
child per dose for 15% increased vaccination rate. While
OPTION Two would require an additional programmatic cost
of $ 0.73, $ 0.84, and $ 1.18 for 10%, 15%, and 25% increased
vaccination rate, respectively, including the cost of printing
vouchers and staff payment for nurses working in the expanded
vaccination sites in hospitals (Table 5). OPTION Two also
Table 3. Impact of illustration potential options to increase influenza vaccination rate among children (6 months to 14 years) in
China.
Measures Input variable Value Source
OPTION One: recall/text
message reminder
Impact of increasing vaccination rate (%) 5, 10, 15 Eelko Hak, et al, 2000 [17] and
assumption
Cost of EPI system (US$) Prior: $1.69 Assumption
If vaccination rate increases 5% same with prior $
If vaccination rate increases 10% same with prior $
If vaccination rate increases 15% 1.5 times of prior $ Assumption






Impact of increasing vaccination rate (%) 10, 15, 25 Rancé F, et al, 2008 [22], Daley
MF, et al, 2004 [23], Britto MT,
et al, 2007 [24] and assumption
Cost of EPI system (US$) Prior: $1.69 Assumption
If vaccination rate increases 10% same with prior $
If vaccination rate increases 15% 1.5 times of prior $
If vaccination rate increases 25% 2.5 times of prior $
Cost of measure (US$) 0.73, 0.84, 1.18
Voucher print cost (per copy) 0.07 Assumption
Staff cost 0.033, 0.050, 0.100 Assumption
Staff payment per person month 443.16
Staff working months 6
Staff working time (%) 25, 50, 50
Number of hospital expanded
If vaccination rate increases 10% In general hospitals (mean = 745,
range 500–892)
Assumption
If vaccination rate increases 15% In general hospitals and half of the
other hospitals (mean = 922, range 627–1102)
If vaccination rate increases 25% All hospitals (mean = 1117, range 768–1319)
Footnotes: OPTION One includes measures of a single telephone reminder. OPTION Two includes a comprehensive measure of sending a free vaccination voucher and
expanding the vaccination sites in hospitals, with one nurse working in each site.
doi:10.1371/journal.pone.0087590.t003
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assumes that the government is paying for the vaccine, which
means an additional $3.95 per child per dose.
The additional net cost of OPTION One for 5% and 10%
influenza vaccination rate increase was more than $ 2.5 million for
both age groups. The additional net cost of OPTION One for a
15% increase in the 60 months to 14 years age group was around $
3.9 million, more than triple that for the 6–59 months age group
(approximately $ 1.1 million) (Table 5).
The additional net cost of OPTION Two was much higher
than that of OPTION One. The mean additional net cost of
OPTION Two was around $ 9–12 million and $ 26–40 million for
the 6–59 months and 60 months to 14 years age group,
respectively (Table 5).
Health Outcomes: The additional numbers of MAC averted
by OPTION One for the 6–59 months age group were 6,518 for a
5% increase in influenza vaccination rate, 6,829 for 10% increase,
and 7,139 for a 15% increase, around double that of the 60
months to 14 years age group. Similar results were found for
numbers of MAC averted by OPTION Two for both age groups
(Table 5).
Cost Effectiveness: In comparison with no vaccination, the
mean (range) of MAC averted by the current self-payment policy
for the two age groups (6 to 59 months and 60 months to 14 years)
was 1,465 (23,11,132) and 792 (36,4,247), respectively, during
the studied five influenza seasons. The total influenza vaccination
program cost to government for the two age groups was $ 6,983
and $ 17,918, and the CER was $ 0 (211,51) and $ 37 (6,125)
per case adverted, respectively. In comparison with the current
policy, the ICER of alternative strategies, OPTION One-
telephone reminder and OPTION Two-comprehensive package,
decreased as influenza vaccination rate increased. For instance,
the highest ICER for OPTION One was $28,118 at a vaccination
rate of 5% for children aged 60 months-14 years, but as the
vaccination rate increased to 15% the ICER was reduced to
$5,838. In OPTION Two, the highest ICER was found to be
$113,757 for children 60 months-14 years at a vaccination rate of
10%, but when the vaccination rate increased to 25% the ICER
decreased to $36,279. In both OPTIONs, it is concluded that
vaccinating children aged 6–59 months is more cost-effective than
vaccinating older children (Figure 2). The province specific cost
effectiveness of the two OPTIONs is in Table S6 in Appendix S1.
Discussion
Under the current situation, the influenza vaccination program
is more cost-effective among children 6 to 59 months than children
60 months to 14 years old. It costs $0 ($-11,$51) per case averted
among children aged 6–59 months, while it costs $37 ($6,$125)
among children aged 60 months to 14 years old per case averted.
Cost-savings was observed among children 6–59 months when the
influenza virus was more active and the vaccination rate was
relatively high.
The price and demand curve (Figure 1) illustrated that reducing
the price of influenza vaccination to parents has a limited effect on
increasing the vaccination rate. Alternative strategies are needed in
order to increase coverage and thus prevent more influenza cases
and related economic loss. Our model was built to demonstrate
the potential impact of various policy options.
Both alternative OPTIONs demonstrated in our model had a
broad range of ICERs, OPTION One-sending reminder ranged
from $590 to $28,118, while OPTION Two-comprehensive
measures ranged from $3,753 to $ 113,757.
Switching from the current policy to the alternative OPTION
would dramatically increase the vaccination program cost, from
$0.03 to more than $5.64 per person per dose at the highest. It
requires a significant expenditure. Meanwhile, health care cost
saved from additional case averting was relatively low. The
estimated cost of influenza outpatient and inpatient was $11.28
and $284.44, which was much lower than that in other countries.
Furthermore, the current reimbursement rate of health insurance
for children in the four provinces was estimated 19.25% based on
a survey [13]. So we anticipate that in places with higher medical
cost or better health insurance coverage, an influenza vaccination
program will save more health care costs.
The health care utilization pattern revealed in this study may
also be the reason for the relatively small number of MAC cases
averted. There appeared to be a higher rate of visits to the hospital
among patients with severe disease than mild. The rate of
outpatients per hospitalization is notably low (i.e. one hospitalized
SARI case per 6–9 outpatients) compared to the rate of other
countries. For example, in the U.S. the rates of outpatient visits
and hospitalizations vary greatly by age and season. The risk of
hospitalization for 6–23 month old children, given an outpatient
visit, can vary, from one hospitalization for every 18 to 42
outpatient visits. Among older children, where the risk of
hospitalization drops, the rate can increase to 52 [26–27].
The wide range of ICERs of the two alternative OPTIONs
(mean range of two OPTIONs: $1,600,$87,908) were associated
with the large variability in the four provinces, in terms of
population size, social economic level, health service utilization,
influenza prevalence, influenza vaccination coverage rate, etc. It
indicated that in a country with huge disparities like China,
decision-making may require more specific data to account for
different situations. Our model allows for more precise estimates of
influenza prevalence, vaccine effectiveness, disease associated
medical costs, and increase in vaccination coverage rate by
Table 4. Cost effectiveness of current influenza vaccination intervention by province and age group in four provinces without
subsidy policy in China, comparing with no vaccination.
Age group
Mean # MAC averted
(range) Mean $ of program (range) Mean $ Net cost(range)
Mean CER for one MAC averted
(range)
6–59 ms 1,465(23,11,132) 6,983(837,36,209) 211,430(2111,829,2,411) 0(211,51)
60ms-14yrs 792(36,4,247) 17,918(2,677,92,195) 11,965(1,851,59,412) 37(6,125)
ms: months; yrs: years
Footnotes:
MAC: medically attended cases including both outpatient and inpatient.
CER: cost-effectiveness ratio. Population number of 6–59 ms and 60 ms-14yrs was 14,301,091 and 45,737,342, respectively.
The mean (range) of influenza vaccination coverage rate of 6–59 ms and 60 ms-14yrs was 11.85% (1.18%–37.69%) and 10.81% (1.18%–39.09%).
Please see Table S4 and S5 in Appendix S1 for data of season and province specific.
doi:10.1371/journal.pone.0087590.t004
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options and other inputs. It is not limited to the illustrated
OPTION One and OPTION Two. It can be a useful tool for
evaluation of other alternative strategies, as well as among other
populations.
There are a number of limitations to this study, mostly due to
lack of available data. We again stress that the objective of this
study is to help public health officials assess the value of both
investing in such potential programs, as well as collecting
additional data to replace the assumptions used here. Although
there is vast literature on the epidemiology of influenza, specific
data were not always available, thus we had to make some
assumptions. For example, to estimate the number of cases, we
assumed that outpatient visit (p1) was constant throughout the
year. It is possible that there is a seasonal pattern to this value, with
an increase during influenza circulation months, which would
increase our estimate of influenza cases. On the other hand, we
used 24 weeks for the influenza season, which may overestimate
the rate of cases seeking medical care for influenza.
Also, the cost of illness from the survey may be biased since
study participants came from SARI sentinel surveillance hospitals
and most were severe cases. However, it was much lower than the
$624 per hospitalized case reported in the Suzhou study [28]. The
difference may be influenced by local economics as our study sites
are less developed than Suzhou. If hospitalization cost in our
model increased to $624 (the governmental cost would increase
from $54.67 to $120.12), we would have lower ICERs. It implied
that in places with higher economic burden of influenza, the
vaccination strategies could be more cost-effective.
Our model is a static model, which does not take into account
an intervention’s impact upon onwards transmission. This model
only incorporates the direct effect of a vaccine, that of protecting
an individual from getting sick, whereas a dynamic model (e.g. an
ordinary differential equation model) will take into account
onwards transmission. Hence, this model is used as a tool to
communicate to policy-makers the various options available and
their relative impact. Its strengths include the fact that it is
relatively simple and easy-to-understand, despite its many
limitations.
Furthermore, we used the perspective of the health care system,
which only captured the cost and benefit to the health care system.
Many studies have shown that lost productivity due to influenza
infection among children is substantial [29]; therefore, a more
comprehensive societal viewpoint may lead to different cost-
effectiveness ratios.
Conclusion
The spreadsheet-based model we developed is a useful tool in
identifying the elements for the cost-effectiveness analysis of using
alternative strategies to increase influenza vaccination coverage
rate in children. However, to produce more accurate estimates of
cost-effectiveness among vaccination policies, more data are
needed.
Supporting Information
Appendix S1 File includes Tables S1-S4. Table S1. General
information of the five provinces/municipalities. This table
provides general information, including areas, overall population,
GDP per capita and population aged 6 months to 14 years, of the
five provinces (the four studied province Shandong, Henan,
Hunan, Sichuan and the compared municipality Beijing). Table
S2. Epidemiologic inputs by province, season, and age group. This
table showed the epidemiologic inputs that were used to calculate
case numbers by province, season and age group from season 05/
06 to 10/11, excluding 09/10 the pandemic season. Table S3.
Current situation: influenza vaccination coverage rates among
target populations by province, season and age group, influenza
vaccine effectiveness by season for all ages. This table used data of
vaccination coverage rate and effectiveness of influenza vaccine by
province from season 05/06 to 11/12, excluding 09/10 the
pandemic season. Table S4. Number of influenza cases and cases
averted by vaccination program. It showed the calculation results
Figure 2. Incremental cost effectiveness ratio (ICER) of two potential strategies to increase influenza vaccination coverage rates
among children by age groups in China comparing with the base situation of current policy. OPTION One includes a single telephone
vaccination reminder. OPTION Two includes comprehensive measures of free vaccination voucher, and expanding vaccination sites in hospital clinics.
The bars in each column shows the ranges due to differences in input values such as rates of influenza like illness (ILI), vaccine effectiveness, and
program costs (c.f., Tables 1 and 2).
doi:10.1371/journal.pone.0087590.g002
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of number of cases and cases averted by the vaccination program,
comparing with no vaccination, from season 05/06 to 10/11,
excluding 09/10 the pandemic season. Table S5. Current
situation: Cost effectiveness of influenza vaccination program in
season 05/06-10/11, 09/10 not included; by province, season and
age group. Demonstration of results on cost- effectiveness of
comparing the current pay-out-of-pocket policy with no vaccina-
tion. Table S6. A: cost-effectiveness of OPTION 1-reminder, by
province and age group. Demonstration of results on cost-
effectiveness of comparing the current situation with two
OPTIONS: OPTION 1 reminder and OPTION 2- sending free
influenza vaccination voucher and expanding vaccination sites.
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